BioImagene Announces Board Expansion and Appoints Biotechnology Veteran G Steven Burrill as Chairman.CUPERTINO, Calif. -- BioImagene, the leading provider of innovative and affordable digital pathology solutions for cancer diagnosis and pre clinical research, today announced the appointment of G Steven Burrill as chairman of the board. The company also announced the appointment of two new board members. The new members include Mr. Taras Silecky of Ascension Health Ascension Health is a non-profit company that operates a network of hospitals and related health facilities in the United States. It is the nation's largest Catholic and largest non-profit health system[1]. Ventures and Dr. Ajit Singh For the founder and chief of the political party Rashtriya Lok Dal in Uttar Pradesh, India, see Chaudhary Ajit Singh. Ajit Singh was the Maharaja of Marwar Jodhpur Rajasthan and the son of Maharaja Jaswant Singh. , CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of the Image and Knowledge Management business of Siemens Healthcare who will join as an independent board member. These announcements come at the heels of the recent closing of a $26 million series D financing round led by Burrill & Company, Ascension Health Ventures, National Healthcare Services as well as existing investors Artiman Ventures and ICCP (Institute for Certification of Computing Professionals, Des Plaines, IL, www.iccp.org). An organization founded in 1973 that offers industry certification and worldwide test centers. Ventures Mr. Steven Burrill said, "We are delighted to join a distinguished group of investors and an experienced management team. Digital pathology, riding on the convergence of innovations in biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. , pathology and imaging technology is primed for personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. supporting our Healthcare Vision 2020."
"We are fortunate to have the insight and experience of Mr. Burrill, Dr. Singh and Mr. Silecky," said Mohan Uttarwar CEO, BioImagene. Mr. Uttarwar continued, "Their addition, along with our world class management team and the infusion of capital will enable BioImagene extend its dominant position in technology innovation and business models. We are now prepared for a full scale operation." Dr Ajit Singh said, "Pathology is poised for the widespread adoption of technology just as radiology was, ten years ago. Technology focused companies using digital pathology applications will experience the inherent value of greater efficiency, productivity and standardization in pathology workflows. More importantly, there are some innovations that are possible only in the digital world, such as use of knowledge-based algorithms, data mining, and decision support." "Hospitals are entering the digital age and digital pathology is a major step towards an integrated workflow and EMR (ElectroMagnetic Radiation) The emanation of energy from everything in the universe. Although the EMR from electrical and electronic devices is typically measured for practical, every-day situations, every object, including humans, emanates energy. . It enables a quick and efficient exchange of information ultimately improving the speed and quality of patient care with greater levels of accuracy," commented Mr. Taras Silecky. About BioImagene BioImagene is a leading provider of total digital pathology solutions for applications including clinical diagnostics and drug discovery. BioImagene products are FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. -cleared for specific clinical applications, and are intended for research use for other applications. www.bioimagene.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion